Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1968 1
1970 2
1971 3
1972 5
1973 6
1974 9
1975 12
1976 12
1977 13
1978 14
1979 6
1980 26
1981 15
1982 20
1983 26
1984 21
1985 15
1986 21
1987 20
1988 13
1989 11
1990 17
1991 12
1992 8
1993 25
1994 4
1995 14
1996 9
1997 4
1998 6
1999 4
2000 7
2001 1
2002 9
2003 1
2004 5
2005 4
2006 5
2007 11
2008 1
2009 4
2010 4
2011 8
2012 3
2013 6
2014 6
2015 3
2016 3
2017 4
2018 1
2019 1
2020 2
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

455 results
Results by year
Filters applied: . Clear all
Page 1
Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial.
Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S, Gualandro DM, de Oliveira Junior MT, Sabti Z, Müller B, Noveanu M, Socrates T, Ziller R, Bayés-Genís A, Sionis A, Simon P, Michou E, Gujer S, Gori T, Wenzel P, Pfister O, Conen D, Kapos I, Kobza R, Rickli H, Breidthardt T, Münzel T, Erne P, Mueller C; GALACTIC Investigators, Mueller C, Erne P, Müller B, Rickli H, Maeder M, Tavares de Oliveira M Jr, Münzel T, Bayés-Genís A, Sionis A, Goudev A, Dimov B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Freese M, Vögele J, Meissner K, Martin J, Strebel I, Wussler D, Schumacher C, Osswald S, Vogt F, Hilti J, Barata S, Schneider D, Schwarz J, Fitze B, Hartwiger S, Arenja N, Glatz B, Herr N, Isenrich R, Mosimann T, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Freese M, Vögele J, Meissner K, Martin J, Strebel I, Wussler D, Schumacher C, Osswald S, Vogt F, Hilti J, Barata S, Schneider D, Schwarz J, Fitze B, Arenja N, Rentsch K, Bossa A, Jallad S, Soeiro A, Georgiev D, Jansen T, Gebel G, Bossard M, Christ M. Kozhuharov N, et al. JAMA. 2019 Dec 17;322(23):2292-2302. doi: 10.1001/jama.2019.18598. JAMA. 2019. PMID: 31846016 Free PMC article. Clinical Trial.
Early intensive and sustained vasodilation was a comprehensive pragmatic approach of maximal and sustained vasodilation combining individualized doses of sublingual and transdermal nitrates, low-dose oral hydralazine for 48 hours, and rapid up-titration of angiotensin-conv …
Early intensive and sustained vasodilation was a comprehensive pragmatic approach of maximal and sustained vasodilation combining individual …
The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT).
Wiggers H, Køber L, Gislason G, Schou M, Poulsen MK, Vraa S, Nielsen OW, Bruun NE, Nørrelund H, Hollingdal M, Barasa A, Bøttcher M, Dodt K, Hansen VB, Nielsen G, Knudsen AS, Lomholdt J, Mikkelsen KV, Jonczy B, Brønnum-Schou J, Poenaru MP, Abdulla J, Raymond I, Mahboubi K, Sillesen K, Serup-Hansen K, Madsen JS, Kristensen SL, Larsen AH, Bøtker HE, Torp-Petersen C, Eiskjær H, Møller J, Hassager C, Steffensen FH, Bibby BM, Refsgaard J, Høfsten DE, Mellemkjær S, Gustafsson F. Wiggers H, et al. Am Heart J. 2021 Jan;231:137-146. doi: 10.1016/j.ahj.2020.09.020. Epub 2020 Oct 9. Am Heart J. 2021. PMID: 33039340 Free PMC article. Clinical Trial.
This investigator driven study will include 1500 HFrEF patients and test in a 2 2 factorial design: 1) if hydralazine-isosorbide dinitrate reduces the incidence of death and hospitalization with worsening heart failure vs. placebo (H-HeFT) and 2) if metformin reduces the i …
This investigator driven study will include 1500 HFrEF patients and test in a 2 2 factorial design: 1) if hydralazine-isosorbide dini …
Efficacy of nifedipine versus hydralazine in the management of severe hypertension in pregnancy: A randomised controlled trial.
Adebayo JA, Nwafor JI, Lawani LO, Esike CO, Olaleye AA, Adiele NA. Adebayo JA, et al. Niger Postgrad Med J. 2020 Oct-Dec;27(4):317-324. doi: 10.4103/npmj.npmj_275_20. Niger Postgrad Med J. 2020. PMID: 33154284 Free article. Clinical Trial.
AIM: The aim of this study was to compare the efficacy and side effects of oral nifedipine and intravenous hydralazine for control of blood pressure (BP) in severe hypertension in pregnancy. ...Time (min) taken to control the BP was similar between the groups (hydralazi
AIM: The aim of this study was to compare the efficacy and side effects of oral nifedipine and intravenous hydralazine for control of …
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators. Taylor AL, et al. N Engl J Med. 2004 Nov 11;351(20):2049-57. doi: 10.1056/NEJMoa042934. Epub 2004 Nov 8. N Engl J Med. 2004. PMID: 15533851 Free article. Clinical Trial.
BACKGROUND: We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy. ...CONCLUSIONS: The addition of a fixed do …
BACKGROUND: We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with …
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, et al. Cohn JN, et al. N Engl J Med. 1986 Jun 12;314(24):1547-52. doi: 10.1056/NEJM198606123142404. N Engl J Med. 1986. PMID: 3520315 Clinical Trial.
For mortality by two years, a major end point specified in the protocol, the risk reduction among patients treated with both hydralazine and isosorbide dinitrate was 34 percent (P less than 0.028). ...The mortality-risk reduction in the group treated with hydralazine
For mortality by two years, a major end point specified in the protocol, the risk reduction among patients treated with both hydralazine
Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial.
Anand IS, Win S, Rector TS, Cohn JN, Taylor AL. Anand IS, et al. Circ Heart Fail. 2014 Sep;7(5):759-65. doi: 10.1161/CIRCHEARTFAILURE.114.001360. Epub 2014 Jun 26. Circ Heart Fail. 2014. PMID: 24970468 Clinical Trial.
BACKGROUND: Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced mortality by 43% and death or first hospitalization for heart failure (HF) by 37% in the African-American Heart Failure Trial (A-HeFT). ...
BACKGROUND: Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced mortality by 43% and death or first hosp …
Plasma norepinephrine and mortality.
Cohn JN. Cohn JN. Clin Cardiol. 1995 Mar;18(3 Suppl I):I9-12. doi: 10.1002/clc.4960181304. Clin Cardiol. 1995. PMID: 7743697 Free article. Review.
Data from the V-HeFT II show that at 2-year follow-up, a progressive rise of plasma norepinephrine was observed in both treatment arms, suggesting that disease progresses despite treatment with either an angiotensin-converting enzyme inhibitor, enalapril, or vasodilator therapy w …
Data from the V-HeFT II show that at 2-year follow-up, a progressive rise of plasma norepinephrine was observed in both treatment arms, sugg …
Combined effects of hydralazine and nitrate on serum biochemistry and left ventricular remodeling in chronic heart failure patients.
Xu W, Qian L, Yuan X, Lu Y. Xu W, et al. Pak J Pharm Sci. 2021 Jan;34(1(Special)):381-386. Pak J Pharm Sci. 2021. PMID: 34275783 Clinical Trial.
To investigate the effects of hydralazine combined with nitrate on serum levels of Adropin and brain natriuretic peptide (BNP), left ventricular remodeling and prognosis in patients with chronic heart failure (CHF). 126 CHF patients were divided into control group (n=13, s …
To investigate the effects of hydralazine combined with nitrate on serum levels of Adropin and brain natriuretic peptide (BNP), left …
A randomized comparison between the hemodynamic effects of hydralazine and nitroglycerin alone and in combination at rest and during isometric exercise in patients with chronic mitral regurgitation.
Roth A, Shotan A, Elkayam U. Roth A, et al. Am Heart J. 1993 Jan;125(1):155-63. doi: 10.1016/0002-8703(93)90069-l. Am Heart J. 1993. PMID: 8417512 Clinical Trial.
Both arteriolar vasodilation with hydralazine and venodilation with nitroglycerin have been shown to favorably alter the hemodynamic profile in patients with chronic mitral regurgitation. Since these therapeutic modalities exert their effects by different mechanisms, this …
Both arteriolar vasodilation with hydralazine and venodilation with nitroglycerin have been shown to favorably alter the hemodynamic …
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes.
Zambrano P, Segura-Pacheco B, Perez-Cardenas E, Cetina L, Revilla-Vazquez A, Taja-Chayeb L, Chavez-Blanco A, Angeles E, Cabrera G, Sandoval K, Trejo-Becerril C, Chanona-Vilchis J, Duenas-González A. Zambrano P, et al. BMC Cancer. 2005 Apr 29;5:44. doi: 10.1186/1471-2407-5-44. BMC Cancer. 2005. PMID: 15862127 Free PMC article. Clinical Trial.
METHODS: Hydralazine was administered to cohorts of 4 patients at the following dose levels: I) 50 mg/day, II) 75 mg/day, III) 100 mg/day and IV) 150 mg/day. ...Toxicity was evaluated using the NCI Common Toxicity Criteria. RESULTS: Hydralazine was well tolerated. T …
METHODS: Hydralazine was administered to cohorts of 4 patients at the following dose levels: I) 50 mg/day, II) 75 mg/day, III) 100 mg …
455 results